Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Evercore ISI Group Initiates Coverage On MiNK Therapeutics with Outperform Rating, Announces Price Target of $30

Evercore ISI Group analyst Maneka Mirchandaney initiates coverage on MiNK Therapeutics (NASDAQ:INKT) with a Outperform rating and announces Price Target of $30.
byBenzinga Newsdesk
November 9, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0

Evercore ISI Group analyst Maneka Mirchandaney initiates coverage on MiNK Therapeutics (NASDAQ:INKT) with a Outperform rating and announces Price Target of $30.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0